Mesenchymal stem cells and multipotent adult progenitor cells (MAPCs) have received a good deal of discussion by scientists as agent for solid organ transplant recipients. Why? Because these cells, with their ability to suppress unwanted immune responses might be able to reduce the need for drugs that suppress the immune system, which have extensive side effects.
The study under discussion today is the clinical course of the first patient of the phase I, dose-escalation safety and feasibility study, MiSOT-I (Mesenchymal Stem Cells in Solid Organ Transplantation Phase I).
The patient received a living-related liver graft, each patient was given one intraportal injection (injection into the portal vein) and one intravenous infusion of third-party MAPC in combination with a low-dose of an anti-tissue-rejection drug.
The results so far are still coming in, but it seems that the administration of the cells is easy and is technically feasible. How well did the patients tolerate them? Quite well it turns out. There was no evidence of acute toxicity associated with infusions of the MAPCs. Also, there was some indication that the patient’s white blood cells were less reactive to foreign substances. However, it is difficult to make definitive statements about the efficacy of this treatment at this time.
Recruitment and follow-up of participants in the MiSOT-I trial continue, and completion of the study is currently projected for autumn 2016.